Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125943 | 0.80 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL20488172 | 0.80 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL7189454 | 0.78 | ADAMTS4 (0.36) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL7189450 | 0.78 | ADAMTS4 (0.36) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL23118418 | 0.76 | ADAMTS4 (0.35) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL19924637 | 0.76 | ALDH1A1 (0.39) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL23296642 | 0.76 | ADAMTS4 (0.35) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL23296644 | 0.76 | ADAMTS4 (0.35) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL19924640 | 0.76 | ALDH1A1 (0.39) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL28906020 | 0.76 | SLC7A5 (0.39) | ADAMTS4TP53SLC7A5GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101490058-A | Antiviral agents | GENELABS TECH INC (US) | 2009-07-22 | — | — | CN | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-101528741-A | Polycyclic viral inhibitors | GENELABS TECH INC (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-101490058-A | Antiviral agents | GENELABS TECH INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | ADAMTS4 1658/4885TP53 1790/4885SLC7A5 2780/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | ADAMTS4 3204/4885TP53 1923/4885SLC7A5 2210/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ADAMTS4 1956/4885TP53 3049/4885SLC7A5 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.